XTX Topco’s Tourmaline Bio TRML Stock Holding History

XTX Topco’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,165	Closed	-$60.8K	–	2159
2023 Q3	$60.8K	Buy	2,165 +177	+9%	+$5.18K	0.01%	1253
2023 Q2	$60.4K	Buy	+1,988	New	+$50.8K	0.01%	1217

Other funds holding TRML

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

XTX Topco's TRML Position: Q4 2023 in Review

XTX Topco sold out of Tourmaline Bio (TRML) in Q4 2023, closing a stake of 2,165 shares — an estimated $60.8K sold.

XTX Topco first reported a position in TRML in Q2 2023 and held it in 2 quarters. The position peaked at $60.8K in Q3 2023. 54 funds tracked by Wall St. Rank hold TRML as of Q4 2023.

XTX Topco reported no remaining Tourmaline Bio position as of Q4 2023 after selling out during the quarter.
XTX Topco sold 2,165 Tourmaline Bio shares in Q4 2023, an estimated $60.8K.
XTX Topco first reported a position in Tourmaline Bio in Q2 2023 and held it in 2 quarters.
XTX Topco's Tourmaline Bio position peaked at $60.8K in Q3 2023.
54 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2023.

Based on XTX Topco's 13F filing for Q4 2023, filed 13 Feb 2024.